Antigen presentation requirements for effective cDC1-based cancer immunotherapy
Josué E Pineda, Tomoyuki Minowa, Li Shen, Yifan Zhou, Allison Dyevoich, Bhakti Patel, Sarah M Schneider, Sunita Keshari, Akata Saha, Morgan N Riba, Jing Wang, Stephanie S Watowich, Matthew M Gubin · 2026
Read Antigen presentation requirements for effective cDC1-based cancer immunotherapy by Josué E Pineda, Tomoyuki Minowa, Li Shen, Yifan Zhou, Allison Dyevoich, Bhakti Patel, Sarah M Schneider, Sunita Keshari, Akata Saha, Morgan N Riba, Jing Wang, Stephanie S Watowich, Matthew M Gubin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13470371.txt.
Description
Pineda and colleagues explore in this 2026 immunology paper what makes a cancer vaccine based on cDC1 cells work. These cells are a type of dendritic cell, an immune scout that shows tumor pieces to T cells so they can attack. Lab-grown versions of these cells had already controlled tumors in mice, but the reasons were not settled.
The team vaccinated mice against melanoma using lab-grown cells. The cells lacked one or both presentation systems, MHC-I and MHC-II. Those systems display protein fragments to T cells. Both systems contributed to tumor control, and having both on the same vaccine cell was needed for a strong response. The lab-grown cells closely matched those found inside tumors, and mice lacking their own cDC1 cells responded poorly, showing the host's cells also help.
Catalog record
| CREATOR | Josué E Pineda, Tomoyuki Minowa, Li Shen, Yifan Zhou, Allison Dyevoich, Bhakti Patel, Sarah M Schneider, Sunita Keshari, Akata Saha, Morgan N Riba, Jing Wang, Stephanie S Watowich, Matthew M Gubin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |